AMRI to Develop and Manufacture Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine

Albany Molecular Research (AMRI) announced on Feb. 25, 2021 that it has been selected to provide support for the development and manufacture of lipid excipients for the Pfizer-BioNTech COVID-19 vaccine.

AMRI has been providing development, scale-up, and manufacturing services for the vaccine at its global R&D production sites, demonstrating its operational flexibility and expertise, AMRI said in a company press release. The company will now join the network of approved manufacturers of the lipid excipients and contribute to the efforts to increase supply.

“We are proud to support Pfizer and BioNTech in this global effort to halt the spread of COVID-19 and prevent further occurrence of this devastating disease,” said John Ratliff, CEO, AMRI, in the press release. “Our response to this pandemic will continue to be both rapid and reliable, reflecting our dedication to quality delivery and scientific integrity. We are committed to playing a vital role in ending this pandemic, from our work in support of antivirals and vaccines to the continued production of essential medicines used for COVID-19 patients.”